Lightnews — Scholar-powered news

Philippe Aftimos, MD

@aftimosp.bsky.social

540 followers 810 following 81 posts

Breast oncologist and clinical researcher 🩺🔬at Institut Jules bordet 🏥. Dad of a 5-yo 🧑‍🧒 and of a cat 🐈. Nature lover 🌳, oud enthusiast 🎼, vegan 🌱, RUSG fan ⚽️💛💙. Proud citizen of Wokistan.

Posts Media Videos Starter Packs

Philippe Aftimos, MD @aftimosp.bsky.social · Jul 12

Rotterdam citytrip and Union Saint-Gilloise 💛💙 at De Kuip

🚂☀️🚤🏟️

1 2

Philippe Aftimos, MD @aftimosp.bsky.social · Jul 8

I am a big fan of @fontainesdc.bsky.social and I discovered their partnership with @bfcdublin.bsky.social at Rock Werchter. I immediately loved the club’s vibes. And that third jersey, wow 🤩

Philippe Aftimos, MD @aftimosp.bsky.social · Jul 3

Rock Werchter 2025

#RW25

Philippe Aftimos, MD @aftimosp.bsky.social · Jun 16

I reviewed for @myesmo.bsky.social new data with a potential clinical impact in HR+/HER2- metastatic breast cancer 👇

ESMO - European Society for Medical Oncology @myesmo.bsky.social · Jun 12

Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations.

Read the opinion by @aftimosp.bsky.social‬ in the #ESMODailyReporter

🔗 buff.ly/QGEixeU

#MBC #BreastCancer #ctDNA

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · May 28

#ESMOMembers – vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee.

📽️ Watch the ESMO President’s message

🔗 Vote now: ow.ly/H7UK50VZR0X

1 5

Philippe Aftimos, MD @aftimosp.bsky.social · May 24

Cool simultaneous illustration of my talk at the seminar series organised by Institut Jules Bordet to celebrate Clinical Trials Day

Philippe Aftimos, MD @aftimosp.bsky.social · May 17

🇩🇪 🚆 🇧🇪 🚌 🏟️ ⚽️💛💙

1 1

Reposted by Philippe Aftimos, MD

Laurence Buisseret @laubdh.bsky.social · May 16

@hoperugo.bsky.social is discussing the results of the ROSALINE trial, an IIT sponsored by the Institut Jules Bordet that evaluated ROS1 inhibition with neo-adj endocrine therapy in early ILBC #ESMOBreast25 👏🏻 @aftimosp.bsky.social & Soraia Lobo-Martins

1 2

Philippe Aftimos, MD @aftimosp.bsky.social · May 15

Day 2 of #ESMOBreast25 in Munich.

Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC:

emiltatug ledadotin and puxitatug samrotecan

#ESMOAmbassadors @myesmo.bsky.social

2 8

Philippe Aftimos, MD @aftimosp.bsky.social · May 14

Part of the Institut Jules Bordet breast cancer team at #ESMOBreast25

@laubdh.bsky.social

1 1 5

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · May 14

In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups.

Full article in the #ESMODailyReporter

🔗 ow.ly/rtbo50VSyiN

2 3

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · May 14

#ESMOBreast25 Award recipient, Gabriel Hortobagyi, describes the long journey that has led to targeted #BreastCancer therapies and explains how patient involvement is central to advancing research.

Read more in the #ESMODailyReporter

🔗 ow.ly/kqju50VSpOE

1 5

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · May 14

At #ESMOBreast25, refinements in #LiquidBiopsy use are reviewed, including a defined window for ESR1 mutation detection in metastatic #BreastCancer and use of pre-neoadjuvant treatment #ctDNA levels to predict recurrence.

More in the #ESMODailyReporter

🔗 ow.ly/R93050VSChg

2 4

Philippe Aftimos, MD @aftimosp.bsky.social · May 14

The path forward for immunotherapy biomarkers in breast cancer by @marleenkok.bsky.social

#ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social

2 4

Philippe Aftimos, MD @aftimosp.bsky.social · May 14

An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example

#ESMOAmbassadors @myesmo.bsky.social

1 3 7

Philippe Aftimos, MD @aftimosp.bsky.social · May 14

#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social

2 6

Philippe Aftimos, MD @aftimosp.bsky.social · May 13

Sustainable travel 🚆 🌱 🌎 to Munich 🇩🇪 and #ESMOBreast25

#ESMOAmbassadors

@myesmo.bsky.social

1 2 10

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · May 12

@aftimosp.bsky.social @erikahamilton9.bsky.social @marleenkok.bsky.social @ptarantinomd.bsky.social

1 1

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · May 12

#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm
🔗 ow.ly/VtAE50VP4Jf

1 4 6

Philippe Aftimos, MD @aftimosp.bsky.social · May 4

03/05/2025
💛💙

#USGGNK

1 4

Philippe Aftimos, MD @aftimosp.bsky.social · May 1

Floralia Brussels 2025 🌷

floralia-brussels.be/en

1 1

Philippe Aftimos, MD @aftimosp.bsky.social · Apr 27

Reposted by Philippe Aftimos, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · Apr 1

🚀 ESMO is now on Bluesky

This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation.

Join us for the latest in oncology education and information.

#AIOncology #HealthAI #ESMOAI25

3 10 24